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Adverse effects of strain persistence and secretion in milk have been encountered with the Brucella melitensis
vaccine strain Rev.1. Field isolates obtained from vaccinated animals and from a human resembled the vaccine
strain Rev.1 by conventional bacteriological tests. The lack of a specific molecular marker that could specif-
ically characterize the commercial vaccine strain prevented confirmation of the homology of the Rev.1-like field
isolates to the vaccine strain. The composition of the omp2 locus from two gene copies with differences in their
PstI restriction endonuclease sites was used to establish an epidemiologic fingerprint for the omp2 gene in the
Rev.1 vaccine strain. Primers designed to amplify DNA sequences that overlap the PstI site revealed a single
282-bp DNA band common to all Brucella spp. Agarose gel electrophoresis of the PstI digests of the PCR
products from strains 16M and the vaccine strain Rev.1 revealed a distinctive profile that included three bands:
one band for the intact 282-bp fragment amplified from omp2a and two bands resulting from the digestion of
the amplified omp2b gene fragment, 238- and 44-bp DNA fragments, respectively. Amplified fragments of 37
Rev.1-like isolates, including 2 human isolates, also exhibited this pattern. In contrast, DNA digests of all other
Israeli field isolates, including atypical B. melitensis biotype 1 and representatives of the biotype 2 and 3
isolates, produced two bands of 238 and 44 bp, respectively, corresponding with the digestion of both omp2a
and omp2b genes. This method facilitates identification of the Rev.1 vaccine strain in both animals and humans
in Israel.
Brucella melitensis causes a worldwide zoonosis. It is one of
the major causes of abortions in sheep and goats, and the
organism is secreted in the milk of infected animals. People
contract the disease by direct contact with contaminated fetal
membranes or, more commonly, as a result of the consumption
of contaminated unpasteurized milk and cheese products. The
organisms are small, gram-negative coccobacilli that grow in
the host as nonobligatory intracellular pathogens of the reticu-
loendothelial system. Derivatives of tetracycline are often used
to treat human infection, while a slaughter policy is recom-
mended for livestock in order to eradicate the disease (11).
In the late 1950s, Elberg developed a live attenuated vac-
cine, strain Rev.1 (12, 13). It was shown that although the
vaccine prevented abortion, it did not provide protection
against infection. Bosseray demonstrated that different lots of
Rev.1 vaccines showed variable immunogenicity in mice ac-
cording to their level of virulence (5, 6). This study emphasized
the instability of the biological properties of the vaccine strain,
stressing the need for stringent control of vaccine production
(7).
The problems in the laboratory were reflected by similar
results in the field. In South Africa, selection of a few smooth
colonies as seed stock led to production of a virulent vaccine
strain which infected sheep and caused human disease (22, 27,
28).
Throughout the last decade Israel maintained a conservative
vaccination policy in which only young female livestock be-
tween the ages of 2 to 6 months were vaccinated, using a full
dose by the subcutaneous route. Nevertheless, retrospective
data demonstrated that the Rev.1 vaccine led to the adverse
effects of strain persistence in the vaccinated animals and was
occasionally spread horizontally (4, 30). Moreover, in two cases
it was shown that the vaccine strain caused human infection,
demonstrating the zoonotic hazards of its virulence. The fact
that vaccination did not always protect the animals in the field
and the several cases of secretion of the field strain in milk had
proven the inefficacy of the whole vaccination program.
International agencies, in their assistance to developing
countries, suggested that national control programs should de-
pend on a whole-flock vaccination scheme as a cost-effective
method until the prevalence of the disease was reduced. Only
then should test and slaughter be implemented to eradicate the
disease (10). There was opposition to this proposal (4) due to
the adverse effects encountered in the field and the public
concerns of possible risks to the human population following
secretion of the vaccine strain in milk. The absence of a specific
molecular marker that could be associated with the identity of
the commercial vaccine strain prevented those opposing the
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vaccination program from linking Rev.1-like field isolates to
the vaccine strain. By the same token, those in favor of the
program could ignore the risks posed by the Rev.1 vaccine,
using the same rationale.
Data presented below provide evidence supporting the ex-
istence of a PstI site polymorphism in the Brucella omp2 gene.
The PstI digestion pattern of PCR-amplified fragments from
the Israeli isolates was different from that of the prototype
strain 16M. Curiously, the PstI digestion profile of the omp2
amplified fragments from the vaccine strain Rev.1 resembled
that of strain 16M, allowing the differentiation of Rev.1 iso-
lates from B. melitensis field strains in Israel. This achievement
could specifically address the potential misdiagnosis of the
atypical B. melitensis biovar 1 strains as Rev.1 isolates due to
similarities in their phenotypic susceptibility to penicillin.
MATERIALS AND METHODS
Bacterial strains. The bacterial strains used in this study (Table 1) were from
the collection maintained in the Israeli reference laboratory. Brucella field strains
were isolated by conventional methods (1) from milk samples, aborted fetuses,
and placentas. Human isolates were obtained from local medical laboratories.
Strain 16M was obtained from J.-M. Verger, Institut National de la Recherche
Agronomique, Nouzilly, France. Strain biotyping was performed by standard
methods (1). Escherichia coli strain NCTC 9001 was used as a control (for
non-Brucella DNA). Rhizobium meliloti strains 158M and 161M were obtained
from D. Kishinevsky, and Agrobacterium radiobacter strains At5/r and At96216
were obtained from D. Zutra, The Volcani Center, Beit Dagan, Israel. Bacterial
strains other than Brucella were obtained from the Department of Bacteriology,
The Kimron Veterinary Institute, Beit Dagan, Israel, or from the Department of
Clinical Microbiology, the Hebrew University-Hadassah Medical School, Jerusa-
lem, Israel.
Bacterial DNA. To prepare chromosomal DNA, bacterial cells were harvested
in saline and incubated for 20 min at 4°C with lysozyme (4 mg/ml). Sodium
dodecyl sulfate (0.5% [wt/vol]) and proteinase K (200 mg/ml) were then added,
and incubation was continued at 37°C for 1 h. The cell lysate was extracted once
with phenol-chloroform-isoamyl alcohol (1:1:49) and once with chloroform-
isoamyl alcohol (1:24). The purified DNA was alcohol precipitated, resuspended
in TE (50 mM Tris-HCl, 1 mM EDTA [pH 8.0]), and stored at 4°C.
PCR and oligonucleotide primers. The Brucella omp2 gene was used as target
DNA. The forward 5 primer (p1 [TGGAGGTCAGAAATGAAC]) and reverse
3 primer (p2 [GAGTGCGAAACGAGCGC]) of an omp2 gene segment were
obtained from National Biosciences, Inc., Plymouth, Minn.
PCR amplification was performed by the method of Mullis and Faloona (26).
A typical reaction mixture contained 50 mM KCl, 1.5 mM MgCl2, 0.1% (wt/vol)
Triton X-100, 0.2 mg of bovine serum albumin (fraction IV; Sigma) per ml, and
10 mM Tris-HCl (pH 8.5). Each reaction mixture was supplemented with 100
mM each of the four deoxyribonucleotides, 100 ng of sample DNA, and each
oligonucleotide primer. For slide PCR, sample DNA was replaced with brucellae
that were laid on a glass slide, air dried, and fixed by being heated. A sample of
the dried cells was then collected with a needle, the needle was dipped in 10 l
of double-distilled water, and 2 l from this solution was put in the PCR mixture.
Otherwise, sample DNA (2 l from a bacterial cell suspension in double-distilled
water boiled at 100°C for 20 min) was used. Reactions were initiated by adding
0.5 U of Taq polymerase (Appligene, Illkirch, France). The reaction mixture was
covered with 15 l of mineral oil (Sigma) to prevent evaporation. Following hot
start treatment at 95°C for 3 min, PCR was performed with an Eppendorf
Thermocycler (Eppendorf, Hamburg, Germany) as follows: 35 cycles of PCR,
with 1 cycle consisting of 20 s at 95°C for DNA denaturation, 1 min at 50°C for
TABLE 1. Brucella strains used in this study
Strain no. Species Biovar Strain designation Strain type, host, or source
1 B. melitensis 1 16M Prototype strain
2 B. melitensis 1 117790 Human
3 B. melitensis 1 118762 Human
4 B. melitensis 1 (atypical) 9413 Sheep
5 B. melitensis 1 (atypical) 6012 Human
6 B. melitensis 1 (atypical) 124386 Human
7 B. melitensis 1 Rev.1 (vaccine) (ocular lot) Commercial source
8 B. melitensis 1 Rev.1 (vaccine) (subcutaneous lot) Commercial source
9 B. melitensis 1 (Rev.1-like) 5000 Human
10 B. melitensis 1 (Rev.1-like) 204216 Human
11 B. melitensis 1 (Rev.1-like) 134172 Sheep milk
12 B. melitensis 1 (Rev.1-like) 116375 Sheep milk
13 B. melitensis 1 (Rev.1-like) 124596 Sheep milk
14 B. melitensis 1 (Rev.1-like) 225875 Goat’s retropharyngeal gland
15 B. melitensis 1 (Rev.1-like) 226390 Sheep bulk milk tank
16 B. melitensis 1 (Rev.1-like) 226997 Sheep milk
17 B. melitensis 1 (Rev.1-like) 223713 Goat’s membranes from aborted fetus
18 B. melitensis 2 118808 Human
19 B. melitensis 2 160621 Human
20 B. melitensis 2 (atypical) 124906 Human
21 B. melitensis 3 Ether Prototype strain
22 B. melitensis 3 119917 Human
23 B. melitensis 3 119919 Human
24 B. melitensis Rough B115 Reference strain
25 B. melitensis Rough 119056 Human
26 B. abortus 1 544 Prototype strain
27 B. abortus 1 2038 Reference strain
28 B. abortus 1 S19 (vaccine)
29 B. abortus 3 Tulya Prototype strain
30 B. suis 1 S2 (vaccine)
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DNA annealing, and 1 min at 72°C for polymerase-mediated primer extension.
The last cycle included incubation of the sample at 72°C for 7 min. Ten micro-
liters of the amplified product was analyzed by electrophoresis in 1.5% agarose
gels in TEA buffer (20 mM Tris-acetate, 1 mM EDTA [pH 8.0]).
DNA digestion. Restriction enzymes were used according to the manufactur-
er’s instructions (Boehringer GmbH, Mannheim, Germany). The digested DNA
was separated by electrophoresis on either 1.5% agarose gels (wt/vol in Tris-
acetate buffer) or 10% polyacrylamide gels (wt/vol in Tris-borate buffer). DNA
fragments were visualized by staining with ethidium bromide (1.5 g/ml).
RESULTS
Validation of the method with prototype strains. The PCR
was first performed to test specificity by comparing Brucella
species DNAs to the DNAs from several other bacteria, in-
cluding the taxonomically closely related Agrobacterium and
Rhizobium strains (29). A single band with the expected size of
282 bp (19) was obtained only when Brucella DNA was used as
a template. All other bacterial strains and a water sample
failed to produce an amplified fragment (data not shown).
The PCR test was studied with Brucella prototype strains
from two of the three important species, namely, B. melitensis
and B. abortus (field and vaccine strains). In addition, B. suis
vaccine strain S2 was included as a representative of this spe-
cies. As shown in Fig. 1, the DNAs from all the strains pro-
duced a 282-bp band. As shown in Fig. 2, PstI digestions of the
amplified fragments from the strains gave different bands on
agarose gels. B. abortus (lanes 1, 3, 4, and 5), B. suis S2 (lane
8), and B. melitensis biovar 3 (lane 12) digests revealed a single
band, a 238-bp band. Other possible smaller fragments are not
shown on the gel. In comparison, PstI digestion of B. melitensis
strain 16M (prototype for B. melitensis biovar 1 virulent strain
[lane 9]) and strain Rev.1 (a vaccine strain from two different
producers administered by a subcutaneous and an ocular route
[lanes 10 and 11, respectively]) amplified DNAs, included two
visible bands: a large band, which was uncut DNA (lanes 6 and
8), and another band, a 238-bp B. abortus fragment. Other pos-
sible smaller bands are not shown on the gel. The PstI digestion
pattern of the amplified fragment obtained from B. melitensis
strain B115 (a stable rough form obtained from an infected
goat in Malta in the early 1970s) (lane 2) was similar to those
for strains 16M and Rev.1 (lanes 9, 10, and 11, respectively).
The digestion profiles of the same DNAs were analyzed by
polyacrylamide gel electrophoresis, as shown in Fig. 3. The
purpose of this analysis was to identify possible smaller frag-
ments that were not shown by agarose gel electrophoresis. As
can be seen in Fig. 3, besides the 282- and 238-bp DNA bands,
all samples produced an additional identical smaller fragment
which was calculated to be 44 bp. It was calculated that the two
smaller bands together were the same size as the uncut DNA,
confirming the expected PstI restriction pattern for B. abortus
biovar 1 (19).
PstI digestion profile of the omp2 gene amplified fragment
from atypical B. melitensis biotype 1 strains. Atypical B.
melitensis biotype 1 isolates from a human source (isolate
6012) and sheep source (isolate 9413) were described previ-
FIG. 1. Agarose gel electrophoresis of PCR-amplified omp2 gene
fragments from Brucella prototype strains. The figure shows a single
band, a 282-bp DNA fragment. Lanes: M, molecular size ladder (in
base pairs); 1, B. abortus strain 2308; 2, B. melitensis strain B115; 3, B.
abortus strain Tulya; 4, B. abortus strain 544; 5, B. abortus vaccine S19;
6, B. melitensis strain 16M; 7, B. suis vaccine S2; 8, B. melitensis vaccine
strain Rev.1 (subcutaneous lot); 9, B. melitensis vaccine strain Rev.1
(ocular lot); 10, B. melitensis strain Ether.
FIG. 2. Agarose gel electrophoresis of PstI digests of amplified
omp2 gene fragments from Brucella prototype strains. The figure
shows the uncut 282-bp DNA and the larger, PstI-digested DNA frag-
ments. The smaller, 44-bp DNA fragment is not shown. Lanes: 1, B.
abortus strain 2308; 2, B. melitensis strain B115; 3, B. abortus strain
Tulya; 4, B. abortus strain 544; 5, B. abortus vaccine S19; 6, B. melitensis
strain 16M (uncut); M, molecular size ladder (in base pairs); 7, B.
abortus strain 544 (uncut); 8, B. suis S2; 9, B. melitensis strain 16M; 10,
B. melitensis vaccine strain Rev.1 (subcutaneous lot); 11, B. melitensis
vaccine strain Rev.1 (ocular lot); 12, B. melitensis strain Ether.
FIG. 3. Polyacrylamide gel electrophoresis of PstI digests of ampli-
fied omp2 gene fragments from Brucella prototype strains. The figure
shows the three DNA fragments, the uncut DNA and the two PstI-
digested DNA fragments, with sizes of 282, 238, and 44 bp, respec-
tively. Lanes: M, molecular size ladder (in base pairs); 1, B. melitensis
strain 16M (uncut); 2, B. melitensis strain 16M; 3, B. melitensis vaccine
strain Rev.1 (subcutaneous lot); 4, B. abortus vaccine S19; 5, B. abortus
strain 544; 6, B. abortus strain 2308; 7, B. melitensis strain Ether.
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ously (2). We compared the PstI digestion profiles of the omp2
gene amplified fragment obtained from these strains and those
obtained from prototype strains. All Brucella strains produced
identical amplified 282-bp fragments (data not shown). Figure
4 depicts a polyacrylamide gel analysis of the digestion profile
of these DNAs. As can be seen, PstI digestion of the two B.
melitensis atypical strains (lanes 2 and 3) produced a uniform
pattern identical to that obtained for B. abortus strains S19 and
544 (lanes 6 and 7) and to that of B. melitensis biotype 3 (lane
8). The PstI digestions of the amplified fragments from the
commercial vaccine strain Rev.1 and the prototype strain 16M
yielded a different pattern (lanes 4 and 5, respectively). The gel
also shows the smaller, 44-bp band common to all digests.
We then analyzed the digestion profile of the omp2 DNA
fragment of selected human isolates as shown in Fig. 5. The
samples included biovar 1 strains (lanes 1, 2, 3, 4, and 14), a
rough isolate (lane 7), atypical biotype 1 (lane 15) and atypical
biotype 2 (lane 16) strains, and two Rev.1 human isolates
(lanes 10 and 12). In addition, we included the prototype strain
16M (lane 11) and two uncut DNAs from strain Rev.1 (lane 8)
and strain 16M (lane 9). Besides strain Rev.1 (lanes 5 and 6),
Rev.1-like isolates (lanes 10 and 12), and B. melitensis strain
16M (lane 11), all other isolates had similar digestion profiles
(as shown in Fig. 2 for B. abortus strains) and B. melitensis
biotype 3 strain Ether.
PstI digestion profile of the omp2 gene amplified fragment
from B. melitensis Rev.1-like isolates. A total of 23 B. melitensis
biotype 1 field isolates, 5 B. melitensis atypical biovar 1 field
isolates (2), 13 B. melitensis biotype 2 field isolates including 3
atypical strains, and 13 B. melitensis biotype 3 field isolates
were studied. All exhibited the pattern shown for B. abortus
strains (data not shown). In contrast, 37 field isolates with
Rev.1-like bacteriological characteristics produced an identical
PstI digestion pattern (as did the commercial vaccine, strain
Rev.1). A representative selection is shown in Fig. 6, lanes 1, 2,
3, 8, 9, 10, and 11, compared to lanes 4 and 7, respectively.
DISCUSSION
The PCR technique has increasingly been used as a supple-
mentary method in Brucella diagnosis (8, 14, 15, 21, 23, 25).
Recently, a molecular biotyping approach has been proposed
on the basis of restriction endonuclease polymorphism in the
genes encoding the major 25- and 36-kDa outer membrane
proteins of Brucella (9, 17, 20). The omp2 gene exists as a locus
of two nearly homologous repeated copies that differ slightly
among Brucella spp. and biotypes (18). We used this informa-
tion to design specific primers that amplify a 282-bp fragment
FIG. 4. Polyacrylamide gel electrophoresis of PstI digests of ampli-
fied omp2 gene fragments from atypical B. melitensis biotype 1 isolates
from humans and animals compared to prototype strains. The figure
shows the three DNA fragments, the uncut DNA and the two PstI-
digested DNA fragments, with sizes of 282, 238, and 44 bp, respec-
tively. Lanes: M, molecular size ladder (in base pairs); 1, B. melitensis
strain 6012 (human isolate) (uncut); 2, B. melitensis strain 6012 (human
isolate); 3, B. melitensis strain 9413 (sheep isolate); 4, B. melitensis
vaccine strain Rev.1 (subcutaneous lot); 5, B. melitensis strain 16M; 6,
B. abortus vaccine S19; 7, B. abortus strain 544; 8, B. melitensis strain
Ether.
FIG. 5. Agarose gel electrophoresis of PstI digests of amplified
omp2 gene fragments from Brucella field strains. The figure shows the
uncut 282-bp DNA and the larger, PstI-digested DNA fragment. The
smaller, 44-bp DNA fragment is not shown. Lanes: 1, B. melitensis
biotype 1 strain 117790; 2, B. melitensis biotype 1 strain 118762; 3, B.
melitensis biotype 2 strain 118808; 4, B. melitensis biotype 2 strain
160621; 5, B. melitensis vaccine strain Rev.1 (ocular lot); 6, B. melitensis
vaccine strain Rev.1 (subcutaneous lot); 7, B. melitensis rough strain
119056; 8, B. melitensis vaccine strain Rev.1 (subcutaneous lot) (un-
cut); M, molecular size ladder (in base pairs); 9, B. melitensis strain
16M (uncut); 10, B. melitensis biotype 1 strain 5000 (human Rev.1-like
isolate); 11, B. melitensis strain 16M; 12, B. melitensis biotype 1 strain
204215 (sheep Rev.1-like isolate); 13, B. melitensis biotype 3 strain
119917; 14, B. melitensis biotype 3 strain 119919; 15, B. melitensis
biotype 1 atypical strain 124386; 16, B. melitensis biotype 2 atypical
strain 124906.
FIG. 6. Agarose gel electrophoresis of PstI digests of amplified
omp2 gene fragments from Brucella field strains that resemble Rev.1
according to biochemical biotyping. The figure shows the uncut 282-bp
DNA and the larger, PstI-digested DNA fragment. The smaller, 44-bp
DNA fragment is not shown. Lanes: 1, B. melitensis strain 134172; 2, B.
melitensis strain 116375; 3, B. melitensis strain 124596; 4, B. melitensis
vaccine strain Rev.1 (subcutaneous lot); 5, B. melitensis vaccine strain
Rev.1 (subcutaneous lot) (uncut); M, molecular size ladder (in base
pairs); 6, B. melitensis vaccine strain (ocular lot) (uncut); 7, B. meliten-
sis vaccine strain Rev.1 (ocular lot); 8, B. melitensis strain 225877; 9, B.
melitensis strain 226390; 10, B. melitensis strain 226997; 11, B. melitensis
strain 223713.
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(Fig. 1), flanking upstream sequences of the 5 terminus of the
two genes and expanding downstream of the PstI and KpnI
sites (17). We assumed that the sensitivity of the test would be
doubled by selecting duplicated DNA sequences of the two
genes. Moreover, we assumed that because of the existing PstI
site polymorphism between B. melitensis and B. abortus, the
test would distinguish between the two species. According to
the working hypothesis, DNA fragments obtained from B.
melitensis strain 16M should produce three bands, an intact
282-bp fragment from the amplified omp2a gene that lacks the
PstI site and two smaller fragments of 238 and 44 bp, the
products obtained from digestion of the omp2b amplified frag-
ment (17). In contrast, B. abortus DNA should produce only
the two smaller fragments from both genes, a 238-bp fragment
and a 44-bp fragment, respectively (Fig. 2 and 3).
We used this method to study the stability of the omp2 gene
among local B. melitensis isolates derived from small rumi-
nants, cattle, and humans and representing the current Bru-
cella population in Israel. Our data confirmed the expected
paradigm for B. melitensis strains B115, 16M, and the vaccine
strain Rev.1 (Fig. 2, lanes 2, 9, 10, and 11), as well as for B.
abortus (Fig. 2, lanes 3, 4, and 5) and B. suis strain 2 (Fig. 2,
lane 8). The Israeli B. melitensis field isolates from the three
biotypes, including the atypical biotype 1 strains, unexpectedly
exhibited the PstI digestion profile which occurs in B. abortus,
i.e., two bands of 238 and 44 bp, respectively (Fig. 4, lane 3, and
Fig. 5, lanes 1, 2, 3, 4, 7, 13, 14, 15, and 16; also data not
shown).
In a comprehensive study, Meyer has shown that unlike B.
abortus, B. melitensis lacked plasticity in the features charac-
terized by the conventional biotyping methods (24). Our data
indicated that in contrast to these findings, B. melitensis has
undergone genetic diversions in a pattern similar to that pre-
viously shown to occur in other Brucella spp. From the data,
one could infer that the prevailing Israeli biotype 1 strains have
acquired a new PstI site in the omp2a gene (compared to the
sequences established for strain 16M). On the other hand,
strains belonging to biotypes 2 and 3 acquired this change
earlier, since all isolates demonstrated the same pattern, which
was similar to the B. melitensis biovar 3 prototype strain Ether
(Fig. 2, lane 12).
Results obtained by Cloeckaert et al. (9) confirmed these
data, showing that B. melitensis isolates were split between
those with a single PstI site located in the omp2b gene and
those with two PstI sites, one in omp2a and one in omp2b.
Interestingly, from the list presented by Cloeckaert et al., it
can be seen that even Israeli isolates from the 19702 all had
two PstI sites, one in omp2a and the second in omp2b, similar
to the results presented above for isolates from the later pe-
riod. This suggests that the Israeli B. melitensis biotype 1 strains
emerged separately from 16M, a strain that originated in the
United States.
It is interesting that recent field isolates in Mexico produced
a digestion profile of the omp2 amplified gene fragments
similar to that of strain 16M and strain Rev.1 (T. A. Ficht,
personal communication). Our data and those obtained by
Cloeckaert et al. have further shown that the described phe-
nomenon applied not only to strain 16M and Rev.1 but also to
the rough strain B115 and H38 as well (Fig. 2, lane 2) (9). We
could propose, therefore, that at least two separate B. meliten-
sis biotype 1 lines have evolved, one represented by strain 16M
and the other represented by the Israeli isolates. A similar
conclusion was drawn by Cloeckaert et al. regarding the ab-
sence of a BglII restriction site in the omp2b genes of the Israeli
isolates (9).
This study included 37 isolates that according to conven-
tional bacteriological methods were characterized as vaccine
strain Rev.1. The PstI digestion pattern of the omp2 amplified
gene fragments resembled that of strain 16M, the prototype
strain for virulent B. melitensis biovar 1, and that of the vaccine
strain Rev.1 (Fig. 2, lanes 9, 10, and 11). In contrast, the PstI
digestion profile of the omp2a gene amplified fragments from
all other Israeli isolates, representing the three biotypes, de-
picted a reproducible and conserved pattern that was different
from that shown for strains 16M and Rev.1 (Fig. 5, lanes 1, 2,
3, 4, 7, 13, 14, 15, and 16). This suggests that a genetic link
might be established between the prototype strain 16M and the
vaccine strain Rev.1. A few other geographically remote iso-
lates may have shared the same ancestral strain.
Human infection with the vaccine strain Rev.1 in South
Africa has been reported, following horizontal infection among
sheep. Clonal selection of virulent colonies during the prepa-
ration of a working seed stock probably led to production of a
vaccine lot with undesirable characteristics (22, 27, 28). It is
interesting that, in Israel, we also identified a human case of
infection with the vaccine strain Rev.1. The owner of an inten-
sively managed sheep farm was infected with the Rev.1 vaccine
strain 6 months after a series of abortions in ewes and isolation
of Rev.1 from the fetal membranes (3). In a report from South
Africa, the researchers biotyped the isolates by conventional
Brucella biotyping methods, and no direct molecular linkage
was shown between the field isolates and the commercial Rev.1
vaccine strain. To the best of our knowledge, our report is the
first to associate animal and human infection with the vaccine
strain Rev.1 based on molecular identification of the strain.
The resemblance of the phenotypic properties of the vaccine
strain Rev.1 and the atypical strain characterized in Israel (2)
regarding susceptibility to penicillin and dyes has raised the
possibility that the atypical strain had originated from a muta-
tion of the vaccine strain. The unique PstI pattern described for
strain 16M and the vaccine strain Rev.1 has allowed us to
elaborate on this subject by comparing their omp2 gene PstI
digestion patterns. If the atypical strain had originated from a
Rev.1 mutant, its omp2 gene PstI digestion pattern should have
matched that of strain Rev.1 and strain 16M. The contrary
would be true if it had originated from a field strain mutant.
The similarity between the PstI omp2 gene digestion profiles of
the atypical strains and the virulent field isolates (Fig. 4) clearly
implied that the latter was the case, lending a mutation in a
virulent strain to render it susceptible to penicillin and dyes.
The zoonotic competence of the atypical isolates (2) that
caused human infection further supported the idea that these
strains had originated from a virulent strain.
The results presented in this study have highlighted some of
the potential hazards associated with use of the Rev.1 vaccine
in national control programs. It has been argued that vaccine
quality could be impaired if its production did not adhere to
stringent standards (5, 7). Having encountered the adverse
effects of the subcutaneous vaccine, we assumed that the com-
mercial Rev.1 vaccine supplied to Israel originated from a
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defective seed stock, similar to the events described in South
Africa. To overcome these problems, Israel changed the vac-
cine source in November 1997, purchasing it from a company
that had sustained its seed stock on a true Elberg strain (pas-
sage 101, 1970; M. Banai, personal communication). Other
expected advantages of the new vaccine were the safety to
adult animals, attributed to the lower dose (108 CFU instead of
109 CFU), and the method of inoculation as an ocular prepa-
ration (16). Implementation of the new vaccine in whole-flock
vaccination, including vaccination of pregnant animals, led to
outbreaks of abortions in several intensively managed flocks
and isolation of the strain from the milk of the aborting ani-
mals. In this study, besides conventional biotyping, we also
applied the new PCR method to confirm the Rev.1 identity of
the isolates according to the omp2a PstI digestion profile (Fig.
6). This new technique made it possible to associate a second
human case of strain Rev.1 infection in a 15-year-old girl (Fig.
5, lane 12). Since then, the Israeli veterinary services changed
the vaccination policy back to the consensus method of vacci-
nation of only young females, and no additional problems have
been encountered.
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